Xeris Pharmaceuticals Inc (XERS) Stock Price, Quote & News

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 445 5704

Website: www.xerispharma.com

Address:

1375 West Fulton Street, Suite 1300, Chicago, United States

Ithaca2018 Jun. 27 at 1:16 AM

$XERS Princess!

1 · Reply

RM03 Jun. 26 at 11:07 PM

$XERS - I like the steady climb up -

0 · Reply

NewEra8 Jun. 26 at 9:42 PM

$XERS ok, nvm, technically another perfect prediction by Lamar Jackson, we are indeed above 4.75. Thanks for tagging along 😝😝😝

0 · Reply

NewEra8 Jun. 26 at 8:10 PM

$XERS something tells me I am a day early on my prediction, tomorrow we explore new territory north

0 · Reply

Struin Jun. 26 at 7:41 PM

$XERS poor xeris, after all the news still in the $4.It wil be a long way. We shall see, but $6, may be $7 is possible but 10-15 no, only with good partnerships and levo approval.

1 · Reply

Scottyknowsall Jun. 26 at 6:41 PM

$XERS i added a few more today, i got a good feeling about our sales this quarter 😉! good luck longs🍀💪🍀

0 · Reply

maixem Jun. 26 at 4:47 PM

$XERS ascending triangle on the daily. We might brake the 4,75 resistance in the coming days.

0 · Reply

Northwoodspeculator Jun. 26 at 4:31 PM

$XERS

0 · Reply

Alon_R Jun. 26 at 1:42 PM

$XERS Growth trajectory - 🔝🔝 Recorlev growth - 🔝🔝 Based on that fulfillment during August ER and the ER after (already with some VialDx data), I will not be surprised if from that moment forward Xeris will be traded for double digits(or around it) and keep on growing from there, with Recorlev (that should be bigger than nowadays Korlym by Xeris statement). The understanding that Recorlev has so much upside(to say the least), till XP-8121 era basically(and beyond), making this investment very appealing (While it have in the arsenal Gvoke, Keveyis, VialDx and Tech as well).

1 · Reply

NewEra8 Jun. 26 at 1:06 PM

$XERS will this be the day we finally break through 4.75 and go up? Yes, yes it will be.

0 · Reply

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

Jun 3, 2025, 7:30 AM EDT - 23 days ago

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 5 weeks ago

Xeris Announces Details for Analyst & Investor Day

May 8, 2025, 2:15 PM EDT - 7 weeks ago

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 7 weeks ago

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 7, 2025, 11:51 AM EDT - 7 weeks ago

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 1, 2025, 7:00 AM EDT - 2 months ago

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 28, 2025, 8:00 AM EDT - 3 months ago

Xeris Announces Changes to Its Board of Directors

Mar 17, 2025, 8:00 AM EDT - 3 months ago

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Mar 6, 2025, 10:52 AM EST - 4 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 4 months ago

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Feb 27, 2025, 7:00 AM EST - 4 months ago

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Feb 24, 2025, 8:00 AM EST - 4 months ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 5, 2025, 8:00 AM EST - 5 months ago

Xeris to Participate in Upcoming Investor Conferences

Jan 21, 2025, 9:00 AM EST - 5 months ago

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Jan 10, 2025, 7:00 AM EST - 5 months ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 6, 2025, 4:15 PM EST - 6 months ago

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 26, 2024, 7:00 AM EST - 7 months ago

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 8, 2024, 11:50 AM EST - 8 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 8 months ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 8:00 AM EDT - 8 months ago

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Oct 25, 2024, 12:50 PM EDT - 8 months ago

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Oct 11, 2024, 2:00 PM EDT - 9 months ago

Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +

GNRC KLC PHG

Oct 9, 2024, 11:33 AM EDT - 9 months ago

Xeris Biopharma: Time For A Reassessment

Aug 8, 2024, 11:56 AM EDT - 11 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 11 months ago

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Announces CEO Succession Plan

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024

May 30, 2024, 7:30 AM EDT - 1 year ago

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

May 30, 2024, 7:00 AM EDT - 1 year ago

Xeris to Participate in the Jefferies Global Healthcare Conference

May 9, 2024, 12:49 PM EDT - 1 year ago

Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

May 6, 2024, 7:00 AM EDT - 1 year ago

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

May 2, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 30, 2024, 1:28 AM EDT - 1 year ago

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 6, 2024, 12:43 PM EST - 1 year ago

Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:02 AM EST - 1 year ago

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Mar 6, 2024, 7:00 AM EST - 1 year ago

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Feb 28, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Feb 5, 2024, 7:00 AM EST - 1 year ago

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

Jan 10, 2024, 8:00 AM EST - 1 year ago

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

Jan 9, 2024, 1:07 AM EST - 1 year ago

Xeris Biopharma: Speculative Buy, Size Your Position Accordingly

Jan 4, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma Updates Its Outlook for 2023

Dec 27, 2023, 7:00 AM EST - 1 year ago

Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 9, 2023, 3:17 PM EST - 1 year ago

Xeris Biopharma Holdings, Inc. (XERS) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 7:00 AM EST - 1 year ago

Xeris Biopharma Reports Third Quarter 2023 Financial Results

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

Ithaca2018 Jun. 27 at 1:16 AM

$XERS Princess!

1 · Reply

RM03 Jun. 26 at 11:07 PM

$XERS - I like the steady climb up -

0 · Reply

NewEra8 Jun. 26 at 9:42 PM

$XERS ok, nvm, technically another perfect prediction by Lamar Jackson, we are indeed above 4.75. Thanks for tagging along 😝😝😝

0 · Reply

NewEra8 Jun. 26 at 8:10 PM

$XERS something tells me I am a day early on my prediction, tomorrow we explore new territory north

0 · Reply

Struin Jun. 26 at 7:41 PM

$XERS poor xeris, after all the news still in the $4.It wil be a long way. We shall see, but $6, may be $7 is possible but 10-15 no, only with good partnerships and levo approval.

1 · Reply

Scottyknowsall Jun. 26 at 6:41 PM

$XERS i added a few more today, i got a good feeling about our sales this quarter 😉! good luck longs🍀💪🍀

0 · Reply

maixem Jun. 26 at 4:47 PM

$XERS ascending triangle on the daily. We might brake the 4,75 resistance in the coming days.

0 · Reply

Northwoodspeculator Jun. 26 at 4:31 PM

$XERS

0 · Reply

Alon_R Jun. 26 at 1:42 PM

1 · Reply

NewEra8 Jun. 26 at 1:06 PM

$XERS will this be the day we finally break through 4.75 and go up? Yes, yes it will be.

0 · Reply

StarF Jun. 26 at 8:53 AM

$XERS should just had fucking sold jfc a shitshow

0 · Reply

Alon_R Jun. 25 at 10:59 PM

$XERS Putting in constant effort, to increase diabetes awareness. I'm positive it is very beneficial to all sides involved. https://www.linkedin.com/posts/xeris-pharmaceuticals_type1diabetes-diabetescare-diabetes-activity-7343654317188370433-o1KN?utm_source=share&utm_medium=member_android&rcm=ACoAAD8sv-EBpYz2tIVWl8rr7UeOFg2NQz5LFPU

1 · Reply

therealpoub Jun. 25 at 8:08 PM

$XERS So I did a few searches wondering what mAbs Regeneron was working on. REGN7508 going to phase 3 this year could be huge (preventing blood clots while minimizing bleeding risks) Link to press release in 2nd post

2 · Reply

Thian Jun. 25 at 7:37 PM

$XERS Slow and steady. Was a good day.

0 · Reply

SportsBetz Jun. 25 at 5:41 PM

$XERS I deserve this the most.

1 · Reply

Savvy7 Jun. 25 at 5:33 PM

$XERS Above 4.80 and we have green grass to 5.25.

0 · Reply

meistermell Jun. 24 at 11:29 PM

$AKBA $ESPR $GERN $SLS $XERS

0 · Reply

Northwoodspeculator Jun. 24 at 8:23 PM

$XERS treading water

0 · Reply

BuyThisOne Jun. 24 at 4:03 PM

$XERS https://www.researchgate.net/publication/392891186_2070-LB_Modeling_to_Assess_the_Impact_of_Liquid_Stable_Glucagon_for_Mini-dosing_in_Pediatrics-A_Simulated_Pharmacokinetic_and_Pharmacodynamic_Study

0 · Reply

BuyThisOne Jun. 24 at 3:50 PM

$XERS 5 year is looking pretty good today. Can't wait for 2028 when this is $20+ and the gain in 2000%. Might splurge and get some waffle house. Not really ready to start spending money until my net worth is over $10 million.

0 · Reply

c_sonnier Jun. 24 at 1:10 PM

$XERS @LionFox Found a great little nugget. WebMD appears to have combined Gvoke and Baqsimi pages into one, which has caused the reviews to be combined and now patients are being mislead by the reviews. Good reviews for Gvoke are showing as good reviews for Baqsimi, which means the inverse is happening for Gvoke. I've reached out to Allison to let her know of this development and will keep everyone updated when more information is available. Link to new combined WebMD page: https://reviews.webmd.com/drugs/drugreview-177620-baqsimi-nasal?conditionid=&sortval=3&next_page=true Screenshot when the two were separate.

4 · Reply

hotcoldhot Jun. 24 at 12:19 PM

$XERS big, if true

2 · Reply

Market Cap	736.57M
Revenue (ttm)	203.07M
Net Income (ttm)	-54.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27.01%
Debt to Equity Ratio	-6.54

Volume	1,327,300
Avg Vol	2,146,214
Day's Range	N/A - N/A
Shares Out	156.39M
Stochastic %K	90%
Beta	0.71
Analysts	Strong Sell
Price Target	$6.58